Mindset Pharma Files Patent For Psilocybin Synthesis Method & Announces Preclinical Results Demonstrating Effectiveness Of Psilocybin Analogs In Development

Drug discovery company Mindset Pharma Inc. filed for patents for its psilocybin synthesis method on July 27, 2021, and in early August announced preclinical results for compounds from its Family 2, comprised of novel psilocybin/psilocin analogs, and Family 4, comprised of novel DMT/5-MeO-DMT analogs, the active components of psychedelic mushrooms. The company is developing compounds to treat neurological and psychiatric disorders. These compounds have demonstrated superior efficacy, safety and shorter duration of action in head-to-head preclinical comparisons with their reference drugs.

Mindset’s Family 2 compounds are next-generation psilocybin and psilocin analogs optimized . . .